Amgen Appoints Alice Xu as Vice President and General Manager for China

SHANGHAI, Aug. 19, 2021 /PRNewswire/ -- Recently, Amgen announced that the Company has officially appointed Ms. Ailing Xu as Vice President and General Manager, China. She will report to Ms. Meiling Ke, Vice President and General Manager, Asia Pacific. As the head of Amgen China, Ms. Xu will take over the leadership from Ms. Ke, who previously concurrently served as General Manager for China, and will lead the team to further advance Amgen's strategic presence in the Chinese market.

Amgen Vice President and General Manager, China, Ms. Ailing Xu

“I am delighted to welcome Ms. Ailing Xu to the Amgen China team,” said Ms. Meiling Ke. “The Chinese market holds substantial development potential and is one of Amgen’s top ten most important markets globally. Ms. Xu possesses exceptional leadership capabilities, extensive international management experience, and a broad global perspective. I am confident that her joining will usher in a new era for Amgen China, leading the team to drive rapid corporate growth and reach new heights.”

Ms. Xu Ailing stated: “I am honored to join Amgen China. The Chinese market holds significant strategic importance for Amgen’s long-term development. In recent years, Amgen China has achieved rapid growth and delivered remarkable results, bringing innovative products to Chinese patients to help them combat serious diseases. However, substantial unmet patient needs remain in the Chinese market across numerous therapeutic areas, including chronic diseases. I look forward to working alongside the team to fulfill our mission of ‘serving patients,’ and actively collaborating with all stakeholders to provide innovative, high-quality, and accessible treatment options for Chinese patients.”

Ms. Ailing Xu possesses extensive global and regional strategic leadership and general management experience in the pharmaceutical industry. Whether in mature markets facing significant growth pressures or in complex and dynamic emerging markets, she has successfully driven sustainable business growth. Prior to joining Amgen, Ms. Xu held leadership positions across multiple regional markets at Janssen Pharmaceuticals and Roche. She has successfully led organizational transformations, fostering a highly engaged, collaborative, and customer-centric high-performance corporate culture, while accelerating patient access to medicines and shaping local healthcare policy environments.

Ms. Ailing Xu holds a Bachelor of Science in Pharmacy from the University of British Columbia, a Doctor of Pharmacy from the Philadelphia College of Pharmacy and Science, and a Master of Business Administration from the Wharton School of the University of Pennsylvania.